# Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

> **NCT04316169** · PHASE1 · WITHDRAWN · sponsor: **Medical College of Wisconsin**

## Conditions studied

- Solid Tumor
- Advanced Breast Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Hydroxychloroquine 200 mg
- **DRUG:** Faslodex
- **DRUG:** Anastrazole
- **DRUG:** Letrozole
- **DRUG:** Hydroxychloroquine 400 mg
- **DRUG:** Hydroxychloroquine 600 mg

## Key facts

- **NCT ID:** NCT04316169
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-21
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding and PI leaving institution
- **Last updated:** 2022-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04316169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04316169, "Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04316169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*